Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs standard-dose argatroban or enoxaparin during ECMO
2025-524553-13-00Phase 2Authorised
- Sponsor
- University Hospital Ostrava
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in respiratory failure, heart failure (HF), cardiogenic shock and 2 more comparing Argatroban anticoagulation with Enoxaparin anticoagulation (2 arms). Primary endpoint: Primary: Comparative efficacy and safety of anticoagulation therapy. Planned start Mar 2026; status: authorised.
02
Drugs
argatrobanenoxaparin
03
Conditions
respiratory failureheart failure (HF)cardiogenic shockacute respiratory distress syndrome (ARDS)cardiorespiratory failure
Beyond the preview
Go deeper on 2025-524553-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524553-13-00.